Fund: ISHGIH
| iShares Genomics Immunology and Healthcare ETF (Dist) | |
| US46435U1925 | |
| 11-06-2019 | |
| Equity | |
| Equity Sectors - Health Care | |
| BlackRock iShares | |
| BlackRock Fund Advisors | |
| USD | |
| 1,000 | |
| 5% |
| 1M | 3M | 6M | 9M | 1R | 3R p.a. | 5R p.a. | 7R p.a. | 10R p.a. | od vnizku p.a. | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Výkonnosť fondu | -5.87% | -0.80% | 23.70% | -5.87% | -3.56% | -22.78% | - | - | - | N/A | |
| Priemerná výkonnosť (36 meraní) | -1.48% | -13.82% | - | - | - | ||||||
| Volatilita od priemernej výkonnosti | 12.18% | 46.24% | - | - | - |
| Long | Short | Net | |
|---|---|---|---|
| Stock | 99.59% | 99.59% | |
| Bond | |||
| Other | |||
| Cash | 0.41% | 0.41% |
| Aktíva | 1,409 mil. |
| Počet akcíí | 49 |
| Počet dlhopisov | 0 |
| Priebež. popl. | |
| z toho Mng. popl. | 0.47 |
| Výk. prémia | |
| Trans. popl. |
| Dividenda | 0.240 |
| Dividendový výnos | 1.09% |
| Rozhodný dátum | 20-12-2023 |
| Frekvencia výplaty | polročne |
| Giant | 19.35% |
| Large | 18.61% |
| Medium | 15.69% |
| Small | 24.49% |
| Micro | 21.46% |
| P/E | 17.48% |
| P/BV | 2.79% |
| Healthcare | 99.59% |
| Derivatives | 0.41 |
| Výnos do splatnosti p.a. | |
| Modifikovaná durácia |
| United States | 69.09% |
| Canada | 1.11% |
| Latin America | |
| United Kingdom | 4.20% |
| Eurozone | 8.30% |
| Europe - ex Euro | 8.00% |
| Europe - Emerging | |
| Africa | |
| Middle East | |
| Japan | 4.90% |
| Australasia | |
| Asia - Developed | 1.00% |
| Asia - Emerging | 3.00% |
| Emerging Market | 3.00% |
| Developed Country | 96.59% |
| Not Classified |
| Spoločnosť | Subsektor | Váha | Spoločnosť | Subsektor | Váha |
|---|---|---|---|---|---|
| Sarepta Therapeutics Inc | Healthcare | 5.46% | Moderna Inc | Healthcare | 4.7% |
| Merck & Co Inc | Healthcare | 4.53% | Revolution Medicines Inc Ordinary Shares | Healthcare | 4.51% |
| Regeneron Pharmaceuticals Inc | Healthcare | 4.22% | GSK PLC | Healthcare | 4.2% |
| Exelixis Inc | Healthcare | 3.93% | Sanofi SA | Healthcare | 3.81% |
| Incyte Corp | Healthcare | 3.73% | Genmab A/S | Healthcare | 3.55% |